AstraZeneca plc  

(Public, LON:AZN)   Watch this stock  
Find more results for AZN
4,172.20
-18.30 (-0.44%)
Jul 28 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted
Range 4,135.50 - 4,283.20
52 week 40.19 - 4,283.20
Open 4,208.50
Vol / Avg. 2.97M/2.34M
Mkt cap 52.48B*
P/E 64.19
Div/yield 125.00/4.27*
EPS 0.65*
Shares 1.26B
Beta     -
Inst. own     -
*GBP
Jul 30, 2015
Q2 2015 AstraZeneca PLC Earnings Call - 12:00PM GMT+1 - Add to calendar
Jul 30, 2015
Q2 2015 AstraZeneca PLC Earnings Release - 7:00AM GMT+1 - Add to calendar
Jun 15, 2015
AstraZeneca PLC at Citi European Healthcare Conference
Jun 2, 2015
AstraZeneca PLC Analysts and Investors Briefing during the American Society of Clinical Oncology (ASCO) Annual Meeting
  

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin 9.11% 4.73%
Operating margin 15.40% 8.19%
EBITD margin - 29.87%
Return on average assets 3.94% 2.16%
Return on average equity 12.07% 5.75%
Employees 57,500 -
CDP Score - 93 A

Address

- Legal Department, 2 Kingdom Street
LONDON, W2 6BD
United Kingdom - Map
+44-20-73045000 (Phone)
+44-20-76048151 (Fax)

Website links

External links

Analyst Estimates - BusinessWeek
Options - MarketWatch
Director Dealings - Yahoo Finance

Description

AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. The Company discovers, develops and commercializes prescription medicines for Cardiovascular and Metabolic diseases; Oncology; Respiratory, Inflammation and Autoimmunity, Infection, Neuroscience and Gastrointestinal. The Company's medicines include Crestor for managing cholesterol levels; Seloken/Toprol-XL for hypertension, heart failure and angina; Onglyza for Type 2; Iressa for lung cancer; Faslodex for breast cancer; Zoladex for prostate and breast cancer; Pulmicort for asthma; Symbicort for asthma and COPD (chronic obstructive pulmonary); Nexium for acid-related diseases; Seroquel XR for schizophrenia, bipolar disorder and depressive disorder, and Synagis for RSV (respiratory syncytial virus), a respiratory infection in infants. The Company's pipeline includes 133 projects, of which 118 are in the clinical phase of development. AstraZeneca operates in over 100 countries.

Officers and directors

Pascal Soriot Chief Executive Officer, Executive Director
Age: 56
Marc Dunoyer Chief Financial Officer, Executive Director
Age: 62
Fiona Cicconi Executive Vice-President, Human Resources
Ruud Dobber Executive Vice President, Europe
Paul Hudson President, AstraZeneca, US and Executive Vice-President, North America
Bahija Jallal Ph.D. Executive Vice President, MedImmune
Mark Mallon Executive Vice President, International
Luke Miels Executive Vice-President, GPPS
Briggs W. Morrison M.D. Executive Vice President - Global Medicines Development
Menelas Pangalos Executive Vice President - Innovative Medicines